The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
The start of our Phase 3 trial for an H5 influenza vaccine marks a significant milestone
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
The approval, following a positive recommendation from the European Medicines Agency’s CHMP, makes the vaccine valid across all 27 EU member states
IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys
Experts highlighted how robotic-assisted procedures are improving surgical precision, reducing complications, and enabling faster recovery
The newly formed SAB will provide strategic direction across research, clinical development, and regulatory pathways
Spread across 7,000 square feet, the Bengaluru facility is positioned as a purpose-built clinical prevention centre focused on identifying silent, life-threatening diseases in asymptomatic individuals
AI-enabled learning platform to enhance clinical quality, patient outcomes, and staff engagement across Eastern India network
The litigation involved multiple civil lawsuits alleging anti-competitive practices and violations of federal
Subscribe To Our Newsletter & Stay Updated
